MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient With Severe ARDS at ATS Annual Meeting
MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient With Severe ARDS at ATS Annual Meeting
NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced presentation of clinical data on agenT-797 in a complex case of severe acute respiratory distress (ARDS) at the American Thoracic Society (ATS) Annual Meeting. These translational and mechanistic insights build on an expanding dataset of clinical activity for patients with severe ARDS.
2024年5月22日，纽约（环球新闻社）——MiNK Therapeutics，Inc.（NASDAQ:INKT），一家临床阶段的生物制药公司，致力于发现，开发和商业化同种异体，现成的，不变的自然杀伤T细胞治疗癌症和其他免疫介导疾病，今天宣布在美国胸科学会（ATS）年会上公布agenT-797在严重急性呼吸窘迫综合症（ARDS）复杂病例的临床数据报告。这些转化和机制方面的见解是与严重ARDS患者的临床活动不断扩大的数据集相结合而形成的。
"Consistent with our prior publication of the survival benefit of agenT-797 in severe respiratory distress, the observed improvement in this case further demonstrates the potential of allogeneic iNKT cells in this setting," said Dr. Terese Hammond, University of California Los Angeles. "New therapeutic options, like allogeneic cell therapies, are urgently needed to address the critical unmet need in immune-compromised individuals with respiratory distress. I believe this growing body of data illuminates how iNKTs may have an impactful role in treating acute critical illness and merits further investigation."
“与我们之前的agenT-797在严重呼吸窘迫中的生存利益的发表相一致，这种病例的观察到的改善进一步证明了同种异体iNKT细胞在这种情况下的潜力，”加州大学洛杉矶分校的特雷斯·哈蒙德博士说。“像同种异体细胞疗法这样的新治疗选择，迫切需要解决呼吸窘迫的免疫受损个体的严重未满足需求。我认为这个不断增长的数据体系阐明了iNKT在治疗急性重症上可能具有有影响力的作用，并值得进一步研究。”
Clinical Findings
临床发现
- Patient: A 26-year-old chronically immunosuppressed patient post-renal transplant contracted COVID-19 and progressed to severe hypoxemic respiratory failure, requiring veno-venous extracorporeal membrane oxygenation (VV-ECMO).
- Treatment: A single dose of 1x10^9 allogeneic iNKT cells (agenT-797) on hospital day 13.
-
Outcomes: Clinical changes showed a rapid decrease in inflammatory cytokines, including IL-18 following agenT-797 administration, consistent with the data observed in the Phase 1 trial of agenT-797 in COVID-19 ARDS (Hammond, T.C., Nat Commun 2024). The patient was extubated on day 37 and discharged home from the hospital on day 60, weaned off hemodialysis and returned to normal activities of daily living (ADLs) within 6 months of dosing.
- 患者：26岁的慢性免疫抑制患者，在肾移植术后感染COVID-19，并发展为严重的低氧性呼吸衰竭，需要静脉-静脉体外膜氧合（VV-ECMO）治疗。
- 治疗：住院第13天单次使用1 x 10^9同种异体iNKT细胞（agenT-797）。
- 结果：与agenT-797的使用相关的临床改变显示，炎性细胞因子，包括白细胞介素18，在agenT-797给药后迅速下降，这与agenT-797在COVID-19ARDS的1期试验中所观察到的数据一致（Hammond, T.C.，Nat通讯，）。此患者于第37天拔管，并于第60天从医院出院，在6个月的用药中逐渐停止了透析，并恢复了日常生活（ADLs）。汉蒙德，T.C.， 自然通讯 2024）。
The full poster presentation can be found on the Publications page of the MiNK website at https://minktherapeutics.com/publications/.
MiNK网站的出版物页面上可以找到完整的海报演讲稿，网址是https://minktherapeutics.com/publications/.
About MiNK Therapeutics
MiNK Therapeutics简介
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/ or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.
MiNK Therapeutics是一家临床生物制药公司，致力于发现、研发和商业化同种异体不变自然杀伤T细胞（iNKT）疗法，以治疗癌症和其他免疫介导性疾病。MiNK正在推进一系列原生和下一代工程iNKT计划，平台旨在为现成送货提供可扩展和可重复生产的工具。公司总部位于纽约市。欲了解更多信息，请访问https://minktherapeutics.com/或关注@MiNK_iNKT。可能对投资者重要的信息将定期发布在我们的网站和社交媒体渠道上。
Forward Looking Statements
前瞻性声明
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic and curative potential of agenT-797 and iNKT cells the mechanism of action, potency and safety, interim or top-line data, including statements regarding clinical data of agenT-797, the anticipated benefits of agenT-797 and clinical development plans and timelines. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K filed with the SEC. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
本新闻稿包含根据联邦证券法规定的安全港条款发布的前瞻性声明，包括针对agenT-797和iNKT细胞的治疗和治愈潜力，作用机制，效力和安全性，中期或前线数据，包括agenT-797的临床数据，agenT-797的预期好处和临床开发计划和时间表等声明。这些前瞻性声明受到可能导致实际结果明显不同的风险和不确定性的影响。MiNK不断告诫投资者不要过份依赖本新闻稿中包含的前瞻性声明。这些声明仅于本新闻稿发布之日起生效，并且MiNK无义务更新或修订这些声明，除非法律规定的程度要求。所有的前瞻性声明都在其整体上通过这一警示声明得到了明确的合格。
Investor Contact
投资者联系方式
917-362-1370
917-362-1370
Media Contact
媒体联系人
781-674-4428
781-674-4428
Source: MiNK Therapeutics
来源：MiNK治疗